Intrahepatic cholangiocarcinoma (iCCA), the second most common liver cancer after hepatocellular carcinoma, remains one of the most difficult diseases to treat due to its highly hidden and heterogeneous nature. A collaborative team from BGI Genomics and Fudan University’s Zhongshan Hospital has now mapped the molecular “chaos” of iCCA, providing a roadmap for more accurate diagnosis and treatment. The research is published in Cell Reports Medicine.
A 1,341-gene signature to reduce sampling bias
A major obstacle in the treatment of iCCA is the prevalence of intratumoral heterogeneity. Cancer cells from different areas of the same tumor can show unique molecular characteristics, meaning that a single biopsy often fails to capture the full biological environment. Researchers have found that the latest classification methods identify more than a quarter of tumors and two-thirds of the reports of the immune system, depending on the location of the biopsy.
To address this challenge, the team identified low-intratumor heterogeneity/high-intertumor variability (LIHV) genes. This signature of 1,341 genes targets markers that remain consistent within a human tumor but vary greatly between patients. By filtering out the discrepant “noise”, the LIHV design enables a robust and reproducible classification of iCCA into five molecular subtypes, each associated with a unique therapeutic disadvantage:
Inflammatory subtype (SI): It is associated with the poorest condition and is enriched with large bile-type iCCA. These tumors often have KRAS and SMAD4 mutations and show elevated serum CA19-9 and CEA levels. Their microenvironment is characterized by a strong neutrophil infiltration, and the chemokine CXCL5 plays a central role.
Metabolic subtype (SII): Shows the highest burden of tumor transformation and the high expression of many biochemical analysis molecules. Despite the immunosuppressive phenotype, this profile suggests potential for immune checkpoint inhibitors and combination immunotherapies.
Group SIII (SIII-1, SIII-2, SIII-3): Consisting of atypical, immune-silent, and neurodegenerative subtypes, respectively, this group is mainly associated with the subtype of bile-type iCCA and generally shows better clinical results. There are different mutational mechanisms, including the development of BAP1 mutations in SIII-2 and IDH1/2 in SIII-3.
Although previous studies have classified iCCA based on genetic changes or aspects of the tumor microenvironment, this design specifically emphasizes genes that remain stable in tumors, thus reducing sampling bias and improving classification reliability.
Translating subtypes into treatment strategies
Regardless of classification, the real clinical value of this framework lies in its ability to guide treatment decisions. For the subtype of inflammation (SI), which is very aggressive and often resistant to PD-1 inhibition, the study shows for the first time that HSP90 inhibitors can suppress tumor growth. Importantly, these agents appear to sensitize tumors to PD-1 therapy, suggesting a promising combination strategy for high-risk patients. In the lower neurodegenerative phase (SIII-3), tumors show high expression of the immunoassay TIM-3. Experimental evidence shows that dual inhibition of PD-1 and TIM-3 is more effective in controlling tumor proliferation than single therapy. The small metabolic type (SII) presents a paradox: despite being an immunosuppressive phenotype, it produces high levels of many diagnostic molecules. This suggests that combination therapies targeting CTLA-4 and LAG3 may provide an effective strategy to overcome immune resistance. Although these studies are currently in their infancy, they form the basis for future clinical trials tailored to specific molecular profiles.
Functional Biomarkers for Clinical Application
To aid clinical translation, researchers have identified available biomarkers that can serve as alternative markers for each type.
GPRC5A was identified as a specific marker for the inflammatory subtype (SI), showing a sensitivity of 71.4% and a specificity of 88.9%. This marker can help pathologists identify this aggressive form in routine histopathological examination.
VTCN1 (also known as B7-H4) was identified as a marker for group SIII, with a sensitivity of 68.7% and a specificity of 80.6%. In addition, the serum levels of CEA and CA19-9 can serve as non-invasive indicators of the underlying type of inflammation, which supports the integration of molecular features in the flow of clinical activity.
Towards Precision Oncology at iCCA
This study provides a comprehensive “roadmap” to manage the complexity of iCCA diseases by directly linking molecular and behavioral subtypes to targeted therapeutic strategies. The LIHV gene signature effectively reduces the limitations imposed by tumor heterogeneity, enabling small biopsy samples to accurately reflect the entire tumor. Future work will focus on validating this design in different patient populations and developing treatments guided by a clinical trial model. By moving beyond single methods to accurate data oncology, this map holds the promise of significantly improving survival outcomes and quality of life for patients with iCCA.
About BGI Genomics
BGI Genomics, headquartered in Shenzhen, China, is a global provider of integrated precision medicine solutions. Our services cover more than 100 countries and territories, including more than 2,300 medical centers. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.
/ Press Release. These articles from the organization/authors may be occasional, and edited for clarity, style and length. Mirage. The content does not take the positions or sides of the organizations, and all opinions, positions, and decisions expressed here are those of the (authors). See more here.
#Genetic #Roadmap #Boosts #Precision #Therapy #ICC